Search Results
Nov 24, 2025, 07:00 ET BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
nab-paclitaxel).A prespecified interim analysis is planned when 40% of progression-free survival (PFS) events are observed.Sickle Cell Disease (SCD) & Gene TherapyAnnounced that a poster featuring final results from a Phase 1 clinical trial (
More news about: BioLineRx Ltd.
Nov 24, 2025, 06:03 ET Cell Therapy Market Size Set to More Than Double by 2030 -- North America Leads, While Asia-Pacific Emerges as the Fastest-Growing Region, Says Mordor Intelligence
Gene Therapy Market: The Gene Therapy Market Report Segments the Industry Into by Vector Type (Adeno Virus Vector), Indication (Oncology, Rare Metabolic Disorders, and More), Delivery Mode (In Vivo Gene Delivery and Ex Vivo Gene Delivery), End User (Hospitals
More news about: Mordor Intelligence Private Limited
Nov 24, 2025, 05:19 ET Drs. Elliott Brea, Esther Redin, and Gavitt Woodard Announced as Recipients of LUNGevity's Career Development Awards
CenterLung Cancer Initiative-LUNGevity Career Development Award$300,000 total award – in partnership with Lung Cancer InitiativeEGFR gene alterations are found in 15-30% of lung adenocarcinomas (LUADs) and are most effectively treated with targeted therapies. These treatments are initially
More news about: LUNGevity Foundation
Nov 24, 2025, 03:31 ET Dr James Liang Launches HK$500 Million "Genovation Foundation" to Address Low Fertility
declining fertility through three key avenues: economic subsidies, cultural advocacy, and policy research. The name Genovation combines "Gene" and "Innovation", symbolising both the continuity of life and the pursuit of creative solutions to pressing social challenges. This marks another significant
More news about: The Genovation Foundation
Nov 22, 2025, 11:40 ET QURE Investigation Notification: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
On November 3, 2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington's disease, did not provide sufficient evidence to support uniQure's Biologics License Application ("BLA") submission. Specifically,
More news about: Kessler Topaz Meltzer & Check, LLP
Nov 22, 2025, 07:50 ET 2025倫敦•金斯瑞生物科技全球產業論壇圓滿落幕：共話CGT新時代，創寫無限可能
全球領先的生命科學研發與生產服務商金斯瑞生物科技股份有限公司，成功舉辦了2025倫敦•金斯瑞生物科技全球產業論壇。這是該論壇第二次落地歐洲，也是自2020年首次亮相舊金山摩根大通醫療健康大會以來，金斯瑞連續舉辦的第八個全球產業論壇，彰顯出金斯瑞為行業搭建高質量交流平台、推動細胞與基因治療（Cell & Gene Therapy, CGT）產業發展的堅定承諾。本次論壇以「THE NEXT ERA OF CGT IS HERE」為主題，吸引了近400位來自全球的參會者，包括諾貝爾生理學或醫學獎獲得者Craig Mello博士在內的全球科學家、企業領袖及投資人共同圍繞CGT前沿議題：從ex
More news about: 金斯瑞生物科技股份有限公司
Nov 21, 2025, 17:32 ET Exploring the Next Era of CGT and Unlocking Limitless Possibilities: The GenScript Biotech Global Forum London 2025 Wraps Up
traditional therapies often fall short. Gene therapies and nucleic acid medicines offer a way to repair defective genes or intervene at the RNA level to control diseases at their source.Moderated by Dr. Julen Oyarzabal, CSO of Syngoi Technologies SL, the session "Gene Therapy and mRNA Therapeutics" brought
More news about: GenScript Biotech Corporation
Nov 21, 2025, 14:49 ET duBreton Responds to Health Canada's Pause on Cloned-Animal Novel Food Policy
responsibility and believe our governing food authorities should too."Gene-Edited Animals Are Still on the TableduBreton reached out to Health Canada following the novel food announcement and received confirmation, gene-editing technologies are not included in this novel food pause and remain
More news about: duBreton
Nov 21, 2025, 13:30 ET Researchers Highlight Genetic Factors in Pediatric Brain and Spinal Cord Tumors
tumor predisposition syndromes had been previously identified.They found that nearly one in four children (23.3%) carried a genetic change in a gene known to increase cancer risk. Among all patients, 7% (57 children) had already been diagnosed with a known genetic condition linked to tumor development,
More news about: Children's Hospital of Philadelphia
Nov 21, 2025, 12:39 ET Hackensack Meridian John Theurer Cancer Center Unveils Research at the 67th American Society of Hematology Annual Meeting
25-2034) Developing artificial intelligence-based transcriptomic signature for the diagnosis of dark zone lymphoma in patients without MYC gene rearrangement (ABSTRACT 25-7855) A multicenter real-world analysis of combined chemotherapy followed by consolidative radiation versus
More news about: Hackensack Meridian John Theurer Cancer Center
Nov 21, 2025, 09:47 ET Cuidados combinados: como o skincare diário e os procedimentos estéticos se complementam para melhorar a qualidade da pele
Poly-L-Lactic Acid for Improving Skin Quality. Dermatol Surg. Jan 2019. 45; 718-2410. Waibel J, et al. A randomized, comparative study describing the gene signatures of poly-l-lactic acid (PLLA-SCA) and calcium hydroxylapatite (CaHA) in the treatment of nasolabial folds. Poster presented at the IMCAS World
More news about: Galderma
Nov 21, 2025, 07:30 ET Moligo Technologies and Cellectis Demonstrate Potential of Enzymatic Single-Stranded DNA for Non-Viral Gene Editing in Nature Communications
pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready to use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies
More news about: Moligo Technologies
Nov 21, 2025, 06:30 ET Azenta Reports Fourth Quarter and Full Year Fiscal 2025 Results, Ended September 30, 2025
million, up 11% year over year.Organic revenue grew 10% year over year, primarily driven by growth in Next Generation Sequencing and Gene Synthesis, partially offset by a year-over-year decline in Sanger sequencing revenue.Summary of GAAP Earnings Results -
More news about: Azenta
Nov 20, 2025, 14:55 ET How Evf2 lncRNA Advances Research in Brain and Neurodevelopmental Disorders, Upcoming Webinar Hosted by Xtalks
Attendees will gain insight into how Evf2 lncRNA guides enhancer-gene regulation and organizes chromosomal domains during brain development. The featured speakers will discuss the roles of direct RNA binding and ribonucleoprotein recruitment in gene activation and repression. Attendees will understand single-cell
More news about: Xtalks
Nov 20, 2025, 12:00 ET MyOme Launches First Integrated Polygenic Risk Score for Prostate Cancer to Advance Early Detection and Personalized Prevention
the risk of developing prostate cancer, such as BRCA2 or HOXB13, up to 95% of prostate cancer cases occur in men without a known single gene variant but who may still harbor polygenic risk detectable by MyOme's iPRS™ test.² The Prostate Cancer iPRS test integrates data
More news about: MyOme, Inc
Nov 20, 2025, 10:03 ET GB Connections Expands Commercial Leadership, Deepening Customer Partnerships and Driving Strategic Growth
improving performance, reliability or service." These changes build on the strong foundation established under the leadership of Gene Mannella, P.E., who now serves as Chairman and Executive Technology Officer. His continued involvement ensures the values, relationships and
More news about: GB Connections LLC
Nov 20, 2025, 10:01 ET Genomics Market worth $85.09 billion by 2030 with 12.6% CAGR | MarketsandMarkets™
Gene Editing Market
More news about: MarketsandMarkets
Nov 20, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
action] On November 3, 2025, Sarepta disclosed that its late-stage ESSENCE trial for two gene therapies, AMONDYS 45 (casimersen) and VYONDYS 5 (golodirsen), both aimed at treating Duchenne muscular dystrophy, "did not meet statistical significance
More news about: Pomerantz LLP
Nov 20, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of uniQure N.V. - QURE
from the U.S. Food and Drug Administration (FDA) during a recent pre-Biologics License Application (BLA) meeting regarding AMT-130, an investigational gene therapy for Huntington's disease (HD)." The press release stated that, "based on the discussions at the meeting, uniQure believes that the FDA currently
More news about: Pomerantz LLP
Nov 20, 2025, 09:55 ET Oxford-Harrington Rare Disease Centre Announces 2025 Scholars Advancing Promising Treatments
San Francisco, San Francisco, CA, USAGene Therapy for the Progressive, Debilitating, Multisystem COPA Syndrome Mingshan Xue, PhD – Baylor College of Medicine, Houston, TX, USAGene Therapy for the Catastrophic CASK-Related Neurodevelopmental
More news about: Harrington Discovery Institute
Nov 20, 2025, 09:43 ET ViVac Appoints Keren Leshem as Chief Executive Officer, Strengthening Leadership to Advance RNA-Lipid Nanoparticle Immunotherapy Platform
core leadership team includes: Dr. Lior Nissim, Head of the Biomedical Synthetic Biology Lab, who pioneered the first synthetic gene circuit for precise targeting of cancer cells; Prof. Chezy Barenholz, a long-time leader in liposome technology and nanomedicine,
More news about: ViVac Pharma Ltd.
Nov 20, 2025, 09:42 ET Oxford-Harrington Rare Disease Centre Announces 2025 Scholars Advancing Promising Treatments
San Francisco, San Francisco, CA, USAGene Therapy for the Progressive, Debilitating, Multisystem COPA Syndrome Mingshan Xue, PhD – Baylor College of Medicine, Houston, TX, USAGene Therapy for the Catastrophic CASK-Related Neurodevelopmental
More news about: Harrington Discovery Institute
Nov 20, 2025, 09:00 ET ReviR Therapeutics Receives $4.6 Million CIRM Grant to Advance Huntington's Disease Treatment and Announces Key Development Milestone
a neurodegenerative disorder caused by an abnormal expansion of CAG trinucleotide repeats in the huntingtin (HTT) gene. Individuals with HD have more than 36 CAG repeats in the HTT gene, resulting in the production of mutant huntingtin protein, which leads to the synthesis of mutant huntingtin protein
More news about: ReviR Therapeutics
Nov 20, 2025, 08:04 ET BioLife Solutions Unveils the Aby J. Mathew Center for Biopreservation Excellence
BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market, today announced the opening of the Aby J. Mathew Center for Biopreservation Excellence. Located within the company's newly expanded
More news about: BioLife Solutions, Inc.
Nov 20, 2025, 08:00 ET ALS Network and ALS United Announce New Research Grantees
Claire Clelland, PhD, MD, University of California San Francisco for Rapid Screening of a Miniaturized Cas and gRNAs for AAV Delivery of C9orf72 Gene Therapy. Richard Daneman, PhD; John Ravits, MD, University of California San Diego
More news about: ALS Network